Rebeca Font

1.2k citations
34 papers · 884 indexed · h-index 17
Topics
Cervical Cancer and HPV Research (6 papers)Medication Adherence and Compliance (6 papers)Global Cancer Incidence and Screening (4 papers)
Partner nations
SpainUnited StatesFrance

In The Last Decade

Rebeca Font

31 papers receiving 855 citations

Peers

Rebeca Font
Comparison fields: 5 of 88
  • Epidemiology 313
  • Oncology 258
  • Surgery 194
  • Pathology and Forensic Medicine 133
  • Genetics 111
Replace S.M. Ess with:
S.M. Ess Switzerland
Jaume Galcerán Spain
Fabrizio Stracci Italy
Alexandre L. Pavluck United States
S B Love United Kingdom
Colleen McGahan Canada
Alberto Ameijide Spain
Nidhi Gupta India
Patricia Delafosse France
Prasanth Ganesan India
Rebeca Font relative to S.M. Ess Switzerland S.M. Ess's profile →
Citations per field
00.5×3.8×
S.M. Ess · 1×
Citations per year

Countries citing papers authored by Rebeca Font

Since Specialization
Citations

This map shows the geographic impact of Rebeca Font's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rebeca Font with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rebeca Font more than expected).

Fields of papers citing papers by Rebeca Font

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rebeca Font. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rebeca Font. The network helps show where Rebeca Font may publish in the future.

Co-authorship network of co-authors of Rebeca Font

This figure shows the co-authorship network connecting the top 25 collaborators of Rebeca Font. A scholar is included among the top collaborators of Rebeca Font based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rebeca Font. Rebeca Font is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 1
2 0
3 0
4 0
5 7
6 8
7 10
8 4
9 9
10 2
11 70
12 23
13 41
14 9
15 29
16 54
17 24
18 77
19 90
20 130

About Rebeca Font

Rebeca Font is a scholar working on Family Practice, Internal Medicine and Statistics and Probability, having authored 34 papers that have together received 884 indexed citations. Recurring topics across this work include Cervical Cancer and HPV Research (6 papers), Medication Adherence and Compliance (6 papers) and Global Cancer Incidence and Screening (4 papers). The work is most often cited by research in Family Practice (86 citations), Otorhinolaryngology (71 citations) and Oncology (258 citations). Rebeca Font has collaborated with scholars based in Spain, United States and France. Frequent co-authors include F. Xavier Bosch, Josep Alfons Espinàs, Josep M. Borràs, Sílvia de Sanjosé, Sílvia de Sanjosé, Belén Lloveras, Joan Prades, Josep M. Argimón, Chris J.L.M. Meijer and Núbia Muñóz. Their work appears in journals such as Scientific Reports, Journal of Clinical Microbiology and British Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026